Genzyme stock is no more. The French drug giant Sanofi-Aventis is completing its $20 billion tender offer for the Cambridge bio-technology company Genzyme — what used to be the state's largest bio-tech firm. Thursday is the first day with the new boss in charge.
With the new leadership comes a boost in funding for currently stalled drug productions.
"Give the new Genzyme a chance," Sanofi's CEO Chris Viehbacher said. "It is very clear that if you’ve grown up in the bio-tech sector, the big pharma sector is very different. At the same time, we have a number of opportunities."
So, how's Genzyme going to do under the new ownership? WBUR's Curt Nickisch met with Viehbacher.
- Curt Nickisch, WBUR reporter
This segment aired on April 7, 2011.